These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 31273896)

  • 1. Genetic diversity of genotype 6 HCV infections in France: Epidemiology and consequences for treatment strategy.
    Pronier C; Fontaine H; Dorival C; Carrat F; Pol S; Thibault V;
    J Viral Hepat; 2019 Nov; 26(11):1276-1283. PubMed ID: 31273896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Preexisting Hepatitis C Virus Genotype 6 NS3, NS5A, and NS5B Polymorphisms on the
    McPhee F; Ueland J; Vellucci V; Bowden S; Sievert W; Zhou N
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30718256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvir.
    Schnell G; Krishnan P; Tripathi R; Beyer J; Reisch T; Irvin M; Dekhtyar T; Lu L; Ng TI; Xie W; Pilot-Matias T; Collins C
    PLoS One; 2018; 13(10):e0205186. PubMed ID: 30286205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses.
    Welzel TM; Bhardwaj N; Hedskog C; Chodavarapu K; Camus G; McNally J; Brainard D; Miller MD; Mo H; Svarovskaia E; Jacobson I; Zeuzem S; Agarwal K
    J Hepatol; 2017 Aug; 67(2):224-236. PubMed ID: 28343981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphisms associated with resistance to protease inhibitors in naïve patients infected with hepatitis C virus genotype 1 in Argentina: Low prevalence of Q80K.
    Martínez AP; Culasso ACA; Pérez PS; Romano V; Campos RH; Ridruejo E; García G; Di Lello FA
    Virus Res; 2017 Aug; 240():140-146. PubMed ID: 28837817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High frequency of multiclass HCV resistance-associated mutations in patients failing direct-acting antivirals: real-life data.
    Gozlan Y; Bucris E; Shirazi R; Rakovsky A; Ben-Ari Z; Davidov Y; Veizman E; Saadi T; Braun M; Cohen-Naftaly M; Shlomai A; Shibolet O; Zigmond E; Katchman H; Menachem Y; Safadi R; Galun E; Zuckerman E; Nimer A; Hazzan R; Maor Y; Saif AM; Etzion O; Lurie Y; Mendelson E; Mor O
    Antivir Ther; 2019; 24(3):221-228. PubMed ID: 30880684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance assessment of a fully automated deep sequencing platform for HCV resistance testing.
    Rodriguez C; Mercier-Darty M; Soulier A; Poiteau L; Wlassow M; Fourati S; Hézode C; Pawlotsky JM; Chevaliez S
    Antivir Ther; 2019; 24(6):417-423. PubMed ID: 31112134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural Polymorphisms Conferring Resistance to HCV Protease and Polymerase Inhibitors in Treatment-Naïve HIV/HCV Co-Infected Patients in China.
    Zhou K; Liang Z; Wang C; Hu F; Ning C; Lan Y; Tang X; Tucker JD; Cai W
    PLoS One; 2016; 11(6):e0157438. PubMed ID: 27341031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment Response and Drug Resistance Profiling of Genotype 6 of Hepatitis C Virus in HCV/HIV Co-Infected Patients: A Pilot Study from INDIA.
    Gupta E; Samal J; Pandey A; Singh G; Gupta HAS; Agarwal R; Sharma MK
    Viruses; 2022 Apr; 14(5):. PubMed ID: 35632686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequencing Analysis of NS3/4A, NS5A, and NS5B Genes from Patients Infected with Hepatitis C Virus Genotypes 5 and 6.
    Ku KS; Chodavarapu RK; Martin R; Miller MD; Mo H; Svarovskaia ES
    J Clin Microbiol; 2016 Jul; 54(7):1835-1841. PubMed ID: 27147726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of sofosbuvir resistance-associated variants in Brazilian and worldwide NS5B sequences of genotype-1 HCV.
    Peres-da-Silva A; Brandão-Mello CE; Lampe E
    Antivir Ther; 2017; 22(5):447-451. PubMed ID: 28085003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice.
    Osawa M; Uchida T; Imamura M; Teraoka Y; Fujino H; Nakahara T; Ono A; Murakami E; Kawaoka T; Miki D; Tsuge M; Hiramatsu A; Abe-Chayama H; Hayes CN; Makokha GN; Aikata H; Ishida Y; Tateno C; Miyayama Y; Hijikata M; Chayama K
    J Gen Virol; 2019 Jul; 100(7):1123-1131. PubMed ID: 31199224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HCV genotype-1 subtypes and resistance-associated substitutions in drug-naive and in direct-acting antiviral treatment failure patients.
    Gozlan Y; Ben-Ari Z; Moscona R; Shirazi R; Rakovsky A; Kabat A; Veizman E; Berdichevski T; Weiss P; Cohen-Ezra O; Lurie Y; Gafanovich I; Braun M; Cohen-Naftaly M; Shlomai A; Shibolet O; Zigmond E; Zuckerman E; Carmiel-Haggai M; Nimer A; Hazzan R; Maor Y; Kitay-Cohen Y; Shemer-Avni Y; Kra-Oz Z; Schreiber L; Peleg O; Sierra S; Harrigan PR; Mendelson E; Mor O
    Antivir Ther; 2017; 22(5):431-441. PubMed ID: 28067632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular characterization of hepatitis C virus for determination of subtypes and detection of resistance mutations to protease inhibitors in a group of intravenous drug users co-infected with HIV.
    Silva T; Cortes Martins H; Coutinho R; Leitão E; Silva R; Pádua E
    J Med Virol; 2015 Sep; 87(9):1549-57. PubMed ID: 25940586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of
    Brandão R; Marcelino R; Gonçalves F; Diogo I; Carvalho A; Cabanas J; Costa I; Brogueira P; Ventura F; Miranda A; Mansinho K; Gomes P
    Viruses; 2018 Apr; 10(5):. PubMed ID: 29701642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pipeline for specific subtype amplification and drug resistance detection in hepatitis C virus.
    Soria ME; Gregori J; Chen Q; García-Cehic D; Llorens M; de Ávila AI; Beach NM; Domingo E; Rodríguez-Frías F; Buti M; Esteban R; Esteban JI; Quer J; Perales C
    BMC Infect Dis; 2018 Sep; 18(1):446. PubMed ID: 30176817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection.
    Zhou N; Hernandez D; Ueland J; Yang X; Yu F; Sims K; Yin PD; McPhee F
    J Infect Dis; 2016 Jan; 213(2):206-15. PubMed ID: 26170396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of a chimeric hepatitis C replicon encoding a genotype-6a NS3 protease and assessment of boceprevir (SCH503034) sensitivity and drug-associated mutations.
    Aloia AL; Eyre NS; Black S; Bent SJ; Gaeguta A; Guo Z; Narayana SK; Chase R; Locarnini S; Carr JM; Howe JA; Beard MR
    Antivir Ther; 2015; 20(3):271-80. PubMed ID: 25222708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Determination of drug resistance mutations of NS3 inhibitors in chronic hepatitis C patients infected with genotype 1].
    Şanlıdağ T; Sayan M; Akçalı S; Kasap E; Buran T; Arıkan A
    Mikrobiyol Bul; 2017 Apr; 51(2):145-155. PubMed ID: 28566078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of resistance-associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents.
    Eltahla AA; Rodrigo C; Betz-Stablein B; Grebely J; Applegate T; Luciani F; Schinkel J; Dore GJ; Page K; Bruneau J; Morris MD; Cox AL; Kim AY; Shoukry NH; Lauer GM; Maher L; Hellard M; Prins M; Lloyd AR; Bull RA;
    J Viral Hepat; 2017 Jan; 24(1):37-42. PubMed ID: 27666440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.